Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Investment bankers say large pharma and biotech deals are stalling as executives grapple with mercurial White House economic ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected ...

She would grab a quick plate of rice or cassava, soaked in rich stews loaded with oil and meat ... Hypertension, diabetes, cardiovascular disease, chronic respiratory disease, mental health disorders ...

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with ...

Dying from colon cancer in the end stage means that treatments are no longer working or need to be stopped due to side effects. The cancer has spread throughout the body, and the condition is ...

In contrast, up to 55% of all patients with breast cancer have tumours with a HER2-low score, as defined in the DESTINY-Breast04 trial, and approval in this group could unlock $3 billion in ...

A new genomic study reveals how Indigenous traditional farming practices have shaped the evolution of manioc – one of the world's most important staple crops – for the better. The domestication of ...

In the article published in Science, analysis of the genomes of more than 500 modern, herbarium and archaeological cassava plants found the cassava genome to be extraordinarily diverse for a ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies ...